EGFR Mutation as a Predictive Factor to Treatment Response ofTKI (Tyrosine Kinase Inhibitor) in Non-Small Cell Lung CancerStage 4: A Case Report

Authors

Wulyo Rajabto, 1 Divisi Hematologi-Onkologi Medik, Departemen Ilmu Penyakit Dalam, Fakultas Kedokteran Universitas Indonesia/RSUPN Dr. Cipto Mangunkusumo, JakartaFollow
Yohana Kusuma Angkasa, 1 Divisi Hematologi-Onkologi Medik, Departemen Ilmu Penyakit Dalam, Fakultas Kedokteran Universitas Indonesia/RSUPN Dr. Cipto Mangunkusumo, Jakarta

Abstract

Non-small cell lung cancer (NSCLC) typically presents in patients at an advanced stage, with a poor prognosis. The development of epidermal growth factor receptor (EGFR) – tyrosine kinase inhibitors (TKIs) and the systematic identification of EGFR mutations heralded the advent of targeted therapy in lung cancer, transforming the landscape of its treatment and prognosis. This is a case of 37 years-old female patient presented with metastatic bone disease secondary to pulmonary adenocarcinoma EGFR mutation positive which demonstrated a remarkable result to TKI.

References

. Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncology. 2018;29(Suppl.4):iv192-237. 2. McCarthy WJ, Meza R, Jeon J, Moolgavkar SH. Chapter 6: lung cancer in never smokers: epidemiology and risk prediction models. Risk Anal. 2012;32(Suppl.1):S69–84. 3. Assche KV, Ferdinande L, Lievens Y, Vandecasteele K, Surmont V. EGFR mutation positive stage IV non-small-cell lung cancer: treatment beyond progression. Front Oncol. 2014;4(350):1-8 4. Tamura T, Kurishima K, Nakazawa K, Kagohashi K, Ishikawa H, Satoh H, et al. Specific organ metastases and survival in metastatic nonsmall-cell lung cancer. Mol Clin Oncol. 2014;3(1):217–21. 5. Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non–small cell lung cancer. JAMA. 2019;322(8):764-74. 6. Nan X, Xie C, Yu X, Liu J. EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer. Oncotarget. 2017;8(43):75712-26. 7. Lin JJ, Cardarella S, Lydon CA, Dahlberg SE, Jackman DE, Janne PA, et al. Five-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs. J Thorac Oncol. 2016;11(4):556-65. 8. Pirker R, Herth FJ, Kerr KM, Filipits M, Taron M, Gandara D, et al. Consensus for EGFR mutation testing in non-small cell lung cancer. J Thorac Oncol. 2010;5(10):1706-13. 9. Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, et al. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. Cochrane Database Syst Rev. 2016;2016(5):CD010383. 10. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Bazhenova LA, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): non-small cell lung cancer. Fort Washington: National Comprehensive Cancer Network; 2020. p.MS-16.

Recommended Citation

Rajabto, Wulyo and Angkasa, Yohana Kusuma (2021) "EGFR Mutation as a Predictive Factor to Treatment Response ofTKI (Tyrosine Kinase Inhibitor) in Non-Small Cell Lung CancerStage 4: A Case Report," Jurnal Penyakit Dalam Indonesia: Vol. 8: Iss. 1, Article 8.
DOI: 10.7454/jpdi.v8i1.166
Available at: https://scholarhub.ui.ac.id/jpdi/vol8/iss1/8